Pharmaceutical manufacturer Aspen Pharmacare will acquire Swiss drug maker Sandoz’s Chinese subsidiary for up to €92.6m (R1.9bn) as it seeks to expand its footprint in China, it announced on Monday.

It will also sell Sandoz the European commercial rights to a portfolio of four anaesthetic drugs in a linked deal worth up to €55.5m (R1.1bn). ..

Subscribe now to unlock this article.

Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).

There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.

Cancel anytime.

Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.